Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.

Enora LaasJulie LabrosseAnne-Sophie HamyGabriel BenchimolDiane de CrozeJean-Guillaume FeronFlorence CoussyThomas BalezeauJulien GuerinMarick LaeJean-Yves PiergaFabien Reyal

Published in: British journal of cancer (2021)

Although RCB and Neo-Bioscore had similar prognostic performances, RCB showed better performance in BC subtypes, especially in luminal and TNBC. By generating fewer prognostic categories, RCB enables an easier use in everyday clinical practice.

Keyphrases

neoadjuvant chemotherapy
clinical practice
locally advanced
lymph node
sentinel lymph node
papillary thyroid
squamous cell
risk factors
squamous cell carcinoma
rectal cancer
solid phase extraction
radiation therapy
molecularly imprinted
mass spectrometry
clinical evaluation
tandem mass spectrometry